FCF Payout Ratio: 19.46%
Is the FCF payout ratio high or low?
The FCF payout ratio of 19.46% is 56% below its 5-year average of 44.06%, near the low end of its 5-year range (18.15%–125.74%).
3.15% above its 12-month average of 18.86%.
RMD FCF Payout Ratio
Rolling trailing-12-month FCF payout ratio sampled each quarter; raw quarterly payout is intentionally not charted.
RMD Average FCF Payout Ratio Chart
RMD Current vs Average FCF Payout Ratio Chart
RMD FCF Payout Ratio Metrics
FCF PAYOUT RATIO
19.46%
FCF PAYOUT RATIO AVG TTM
18.86%
FCF PAYOUT RATIO AVG 3Y
22.44%
FCF PAYOUT RATIO AVG 5Y
36.10%
FCF PAYOUT RATIO AVG 10Y
40.88%
FCF PAYOUT RATIO AVG 15Y
42.59%
FCF PAYOUT RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+3.15%
CURRENT VS 3Y AVG
-13.30%
CURRENT VS 5Y AVG
-46.10%
CURRENT VS 10Y AVG
-52.41%
CURRENT VS 15Y AVG
-54.31%
CURRENT VS 20Y AVG
N/A
Payout Ratio Comparison
FCF Payout Ratio TTM
19.5%
Earnings Payout Ratio
25.1%
Dividend Yield
1.21%
FCF Yield
5.99%
Annual FCF Payout Ratio History
| Year | Free Cash Flow | Dividends Paid | FCF Payout Ratio |
|---|---|---|---|
| 2025 | $1.66B | $310.88M | 18.7% |
| 2024 | $1.29B | $282.32M | 21.9% |
| 2023 | $559.30M | $258.28M | 46.2% |
| 2022 | $195.11M | $245.34M | 125.7% |
| 2021 | $619.89M | $226.71M | 36.6% |
| 2020 | $696.32M | $225.09M | 32.3% |
| 2019 | $381.71M | $211.71M | 55.5% |
| 2018 | $433.57M | $199.50M | 46.0% |
| 2017 | $342.58M | $186.35M | 54.4% |
| 2016 | $480.10M | $168.13M | 35.0% |
| 2015 | $311.24M | $157.26M | 50.5% |
| 2014 | $310.11M | $141.52M | 45.6% |
| 2013 | $331.04M | $97.20M | 29.4% |
| 2012 | $322.05M | $0 | 0.0% |
| 2011 | $208.19M | $0 | 0.0% |
| 2010 | $126.57M | $0 | 0.0% |
| 2009 | $124.66M | $0 | 0.0% |
| 2008 | $62.06M | $0 | 0.0% |
| 2007 | $13.55M | $0 | 0.0% |
| 2006 | ($3.72M) | $0 | N/A (Loss) |
| 2005 | $31.39M | $0 | 0.0% |
| 2004 | $19.30M | $0 | 0.0% |
| 2003 | $33.65M | $0 | 0.0% |
| 2002 | $7.46M | $0 | 0.0% |
| 2001 | $2.06M | $0 | 0.0% |
| 2000 | $4.11M | $0 | 0.0% |
| 1999 | ($4.30M) | $0 | N/A (Loss) |
| 1998 | ($5.00M) | $0 | N/A (Loss) |
| 1997 | $5.50M | $0 | 0.0% |
| 1996 | $2.00M | $0 | 0.0% |
Formula: FCF Payout Ratio TTM = trailing 4Q dividends paid / trailing 4Q free cash flow × 100
FCF payout and earnings payout:
- FCF represents operating cash flow after capital expenditures
- FCF payout compares dividends paid with free cash flow
- FCF payout above 100% means dividends paid exceeded free cash flow for the period
- Earnings payout compares dividends paid with net income
Reading the series: Use the chart and table to compare dividend payments with cash generation over time.
FCF Payout Ratio Formula & Definition
FCF Payout Ratio measures trailing dividends paid as a percentage of trailing free cash flow. Unlike earnings-based payout, it compares dividends with cash generated after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
FCF Payout Ratio FAQ
- What is the FCF payout ratio for ResMed Inc. (RMD)?
- The FCF payout ratio for RMD stock is 19.46%.
- Is ResMed Inc.'s FCF payout ratio high or low?
- The FCF payout ratio of 19.46% is 56% below its 5-year average of 44.06%, near the low end of its 5-year range (18.15%–125.74%).
- What is the TTM average FCF payout ratio for ResMed Inc. (RMD)?
- The TTM average FCF payout ratio for RMD stock is 18.86%.
- What is the 3Y average FCF payout ratio for ResMed Inc. (RMD)?
- The 3Y average FCF payout ratio for RMD stock is 22.44%.
- What is the 5Y average FCF payout ratio for ResMed Inc. (RMD)?
- The 5Y average FCF payout ratio for RMD stock is 36.10%.
- What is the 10Y average FCF payout ratio for ResMed Inc. (RMD)?
- The 10Y average FCF payout ratio for RMD stock is 40.88%.
- What is the 15Y average FCF payout ratio for ResMed Inc. (RMD)?
- The 15Y average FCF payout ratio for RMD stock is 42.59%.
RMD FCF Payout Ratio History
| DATE | FCF PAYOUT RATIO |
|---|---|
| 2026-03-31 | 19.46% |
| 2025-12-31 | 18.55% |
| 2025-09-30 | 18.15% |
| 2025-06-30 | 18.74% |
| 2025-03-31 | 19.42% |
| 2024-12-31 | 21.37% |
| 2024-09-30 | 21.48% |
| 2024-06-30 | 21.93% |
| 2024-03-31 | 25.78% |
| 2023-12-31 | 28.64% |
| 2023-09-30 | 33.37% |
| 2023-06-30 | 46.18% |
| 2023-03-31 | 62.56% |
| 2022-12-31 | 113.63% |
| 2022-09-30 | 81.54% |
| 2022-06-30 | 125.74% |
| 2022-03-31 | 70.02% |
| 2021-12-31 | 52.97% |
| 2021-09-30 | 58.26% |
| 2021-06-30 | 36.57% |
| 2021-03-31 | 30.87% |
| 2020-12-31 | 29.21% |
| 2020-09-30 | 32.98% |
| 2020-06-30 | 32.33% |
| 2020-03-31 | 43.93% |
| 2019-12-31 | 52.01% |
| 2019-09-30 | 44.16% |
| 2019-06-30 | 55.46% |
| 2019-03-31 | 55.79% |
| 2018-12-31 | 53.35% |
| 2018-09-30 | 51.90% |
| 2018-06-30 | 46.01% |
| 2018-03-31 | 44.26% |
| 2017-12-31 | 53.59% |
| 2017-09-30 | 54.33% |
| 2017-06-30 | 54.40% |
| 2017-03-31 | 50.13% |
| 2016-12-31 | 42.26% |
| 2016-09-30 | 38.66% |
| 2016-06-30 | 35.02% |
| 2016-03-31 | 38.85% |
| 2015-12-31 | 41.03% |
| 2015-09-30 | 45.63% |
| 2015-06-30 | 50.53% |
| 2015-03-31 | 47.75% |
| 2014-12-31 | 46.04% |
| 2014-09-30 | 48.16% |
| 2014-06-30 | 45.63% |
| 2014-03-31 | 40.66% |
| 2013-12-31 | 36.66% |
| 2013-09-30 | 32.34% |
| 2013-06-30 | 29.36% |
| 2013-03-31 | 83.62% |
| 2012-12-31 | 78.72% |
| 2012-09-30 | 65.59% |
| 2012-06-30 | 57.56% |
| 2012-03-31 | 26.94% |
| 2011-12-31 | 27.83% |
| 2011-09-30 | 33.66% |
| 2011-06-30 | 37.80% |
About ResMed Inc.
ResMed Inc. is a leading global medical technology enterprise engaged in the creation, production, distribution, and marketing of healthcare devices and connected digital solutions. The company operates through two primary segments: Sleep and Respiratory Care, and Software as a Service. Its extensive product range addresses a variety of respiratory disorders, encompassing advanced medical and consumer technologies, ventilation devices, diagnostic equipment, mask systems for both clinical and personal use, headgear, and related accessories, alongside dental devices. ResMed also provides sophisticated cloud-based informatics to enhance patient management and operational efficiency. Notable software offerings in its respiratory portfolio include AirView, for remote device monitoring and setting adjustments; myAir, a personalized application designed to support sleep apnea patients with education and troubleshooting for better engagement and adherence; and U-Sleep, a compliance tracking platform for home medical equipment providers. Complementing these are connectivity modules and Propeller solutions. Furthermore, ResMed offers a robust suite of out-of-hospital software. This includes Brightree, a business management platform for various home care service providers (e.g., HME, pharmacy, infusion, orthotics, prosthetics); MatrixCare, providing care management for senior living, skilled nursing, and hospice organizations; and HEALTHCAREfirst, which supplies electronic health records, billing, coding services, and analytics for home health and hospice agencies. ResMed distributes its offerings primarily to sleep clinics, home healthcare dealers, and hospitals via a global network of distributors and a direct sales force, serving approximately 140 countries. Founded in 1989, the company's headquarters are located in San Diego, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Michael J. Farrell